Top Story

First-line fulvestrant extended OS in advanced, ER-positive breast cancer

December 22, 2014

SAN ANTONIO — First-line fulvestrant significantly extended OS compared with anastrozole in women with advanced, ER-positive breast cancer, according to results of the phase 2 FIRST study presented at the San Antonio Breast Cancer Symposium.

Prior research demonstrated fulvestrant (Faslodex, AstraZeneca) was associated with prolonged disease control compared with anastrozole (Arimidex, AstraZeneca) in the second-line setting.

Ixazomib may provide more convenient, effective treatment for multiple myeloma Meeting News CoverageVideo

Ixazomib may provide more convenient, effective treatment for multiple myeloma

December 21, 2014
SAN FRANCISCO — Shaji K. Kumar, MD, professor of medicine at the Mayo Clinic in Rochester, Minn., discusses the experimental agent, ixazomib, which may…
Vosaroxin combination demonstrated improved survival in AML Meeting News CoverageVideo

Vosaroxin combination demonstrated improved survival in AML

December 20, 2014
SAN FRANCISCO — Farhad Ravandi, MD, professor of medicine in the department of leukemia at The University of Texas MD Anderson Cancer Center, discusses data from…

New next-generation sequencing test launched for thyroid nodules

December 20, 2014
Interpace Diagnostics, a molecular diagnostics subsidiary of PDI, Inc., has recently launched a new next-generation sequencing test designed to determine the difference…
In the Journals

ST2 levels predicted acute GVHD, mortality after double-unit cord blood transplantation

December 19, 2014
High levels of the biomarker suppressor of tumorigenicity 2 at 28 days post-cord blood transplantation independently predicted acute graft-versus-host disease, according…
More News Headlines »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
Meeting News Coverage Video
Vosaroxin combination demonstrated improved survival in AML

Vosaroxin combination demonstrated improved survival in AML

December 20, 2014
SAN FRANCISCO — Farhad Ravandi, MD, professor of medicine in the department of leukemia at The University of…
More »
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
morganatic-roan
morganatic-roan